Verastem
Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments to enhance the survival and quality of life for cancer patients. The company markets COPIKTRA, an oral dual inhibitor of phosphoinositide 3-kinase (PI3K), which is approved for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma after previous therapies. Additionally, Verastem is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, currently being studied in combination with immunotherapies for various cancers, including pancreatic and non-small cell lung cancer. The company focuses on targeting critical signaling pathways in cancer to inhibit tumor growth and promote cell death. Verastem has established collaborations with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited, and is headquartered in Needham, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.